We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Method Tracks Gene Activity in the Living Brain

By LabMedica International staff writers
Posted on 04 Jun 2026

Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. More...

Tracking active genes could reveal how the body responds to environmental factors, medication, or disease progression, but current workflows rely on end-point analyses that miss in vivo dynamics. Researchers have now developed a blood-based approach for monitoring targeted gene transcription in living brain tissue.

Rice University (Houston, TX, USA) bioengineers have developed In-vivo Tracking of Active Transcription (INTACT), a method designed to monitor selected genes in living tissue using a standard blood draw. The approach aims to quantify transcriptional activity without removing or damaging tissue. The team describes this as a demonstration of nondestructive gene transcription measurement in the living brain.

INTACT integrates engineered reporter molecules, termed Released Markers of Activity (RMAs), with intracellular sensors that recognize a target messenger RNA (mRNA). Upon detecting the target mRNA, the sensors trigger production and release of RMAs into the bloodstream. The circulating RMAs can then be measured from blood, enabling longitudinal tracking of specific gene activity. Because the targeting sequence is encoded in the genetic construct, the system is presented as programmable for different genes.

The platform was validated in an animal model and was able to track transcriptional activity from three distinct brain regions simultaneously. The authors note that, unlike next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR), which require destruction of the analyzed sample, the new method permits repeated measurements over time in the same organism. The capability to multiplex by gene, neural circuit, or brain region is identified as an area for further development.

The study, “Monitoring in vivo transcription with synthetic serum markers,” was published in Nature Communications on May 27, 2026. The researchers also indicate potential to expand beyond the central nervous system, suggesting applicability to other tissues. They further state that the method is scalable and, in theory, adaptable to any gene sequence included in the construct.

“This is the first demonstration of measuring transcription for targeted genes nondestructively in living tissue. That means that we can actually select which gene we want to study and then see how it expresses over time within the same organism. That allows us to see what happens before, for example, a disease occurs and how gene expression changes as that disease progresses,” said Jerzy Szablowski, assistant professor of bioengineering at Rice and the corresponding author on a study.

Related Links
Rice University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gastrointestinal Panel
Xpert® GI Panel
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.